| 000 | 00883 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250513092625.0 | ||
| 264 | 0 | _c19960829 | |
| 008 | 199608s 0 0 eng d | ||
| 022 | _a0959-8138 | ||
| 024 | 7 |
_a10.1136/bmj.313.7050.170b _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMaynard, A | |
| 245 | 0 | 0 |
_aEvidence based medicine. Cost effectiveness and equity are ignored. _h[electronic resource] |
| 260 |
_bBMJ (Clinical research ed.) _cJul 1996 |
||
| 300 |
_a170-1 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 | _aClinical Medicine |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 | _aHealth Care Rationing |
| 650 | 0 | 4 | _aHumans |
| 773 | 0 |
_tBMJ (Clinical research ed.) _gvol. 313 _gno. 7050 _gp. 170-1 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1136/bmj.313.7050.170b _zAvailable from publisher's website |
| 999 |
_c8686127 _d8686127 |
||